Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8

Dendritic cells (DC) are antigen‐presenting cells with the potential to be a powerful adjuvant in the immunotherapy of haematological malignancy, including myeloma. Recently, human herpesvirus 8 (HHV‐8) infection of dendritic cells in the long‐term bone marrow stromal cultures of patients with myelo...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 1998-03, Vol.100 (4), p.793-796
Main Authors: CULL, G. M, TIMMS, J. M, HAYNES, A. P, RUSSELL, N. H, IRVING, W. L, BALL, J. K, THOMSON, B. J
Format: Article
Language:English
Subjects:
AIDS/HIV
Antigens, CD34
Biological and medical sciences
dendritic cells
Dendritic Cells - virology
Flow Cytometry
Hematology
Herpesviridae Infections - immunology
Herpesvirus 8, Human - isolation & purification
human herpesvirus 8
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
immunotherapy
Medical sciences
Multiple Myeloma - virology
myeloma
Polymerase Chain Reaction
Sensitivity and Specificity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dendritic cells (DC) are antigen‐presenting cells with the potential to be a powerful adjuvant in the immunotherapy of haematological malignancy, including myeloma. Recently, human herpesvirus 8 (HHV‐8) infection of dendritic cells in the long‐term bone marrow stromal cultures of patients with myeloma has been reported. This finding is of great potential importance regarding oncogenesis in myeloma in addition to having significant implications for the use of DC in the immunotherapy of this disease. Therefore DC generated from mobilized blood mononuclear cells (MO‐DC) and purified CD34+ cells (CD34‐DC) of myeloma patients were examined for the presence of HHV‐8 using a sensitive PCR technique. HHV‐8 was not demonstrated in MO‐DC or CD34‐DC and we conclude that these cells remain a suitable vehicle for investigation in the immunotherapy of myeloma.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.1998.00671.x